NEW YORK (GenomeWeb News) – Consumer genomics firm GeneLink reported that its first-quarter revenues dropped 45 percent year over year following the sale of its GeneWize Life Sciences subsidiary.

For the three months ended March 31, the Orlando, Fla.-based company posted $771,664 in revenues, down from $1.4 million a year ago, it said in its Form 10-Q filed with the US Securities and Exchange Commission on Monday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.